High survival rates following atezolizumab consolidation therapy in DLBCL

High-risk diffuse large B-cell lymphoma patients with a complete metabolic response (CMR) after R-CHOP benefitted from atezolizumab consolidation therapy.

Trial included up to 18 cycles every 3 weeks

The phase 2 HOVON 151 study (NL6335204217) investigated the efficacy of atezolizumab consolidation therapy in participants with high-risk DLBCL who had a CMR after R-CHOP therapy (n=109). The included participants received intravenously administered 1,200 mg atezolizumab every 3 weeks for up to 18 cycles. The primary endpoint was disease-free survival (DFS) and Dr Marcel Nijland (University Medical Center Groningen, the Netherlands) presented the study's final analysis.

The 2-year DFS rate was 87.9% (90% CI 81.5–92.1), surpassing the 2-year DFS rate from a historical cohort (≤79% [2]) and meeting the primary endpoint. Moreover, the 2-year overall survival rate was 96.3%. Dr Nijland added that 13 of the 15 relapsing participants received salvage chemotherapy, of whom 77% experienced a second CMR.

Adverse events were reported in 79% of the participants, most commonly being infections (25%), musculoskeletal and connective tissue disorders (9%), and nervous system disorders (9%). The research team noted 10 cases of endocrinopathy and 3 ocular toxicities during the study.

Atezolizumab consolidation therapy after R-CHOP yielded excellent results in participants with high-risk DLBCL who achieved a CMR on R-CHOP. The remarkable 2-year overall survival outcomes and the fact that most participants were chemo-sensitive at relapse support atezolizumab as a consolidation therapy for this population.

Medical writing support was provided by Robert van den Heuvel.

  1. Nijland M, et al. Feasibility and clinical efficacy of atezolizumab consolidation in high risk diffuse large B-cell lymphoma: final analysis of the HOVON 151. Abstract #S236, EHA congress 2024, 13–16 June, Madrid, Spain.
  2. El-Galaly TC, et al. J Clin Oncol. 2015;33(34):3993–3998.